NASDAQ:TELA TELA Bio (TELA) Stock Price, News & Analysis → Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad) Free TELA Stock Alerts $6.28 0.00 (0.00%) (As of 10:02 AM ET) Add Compare Share Share Today's Range$6.24▼$6.2850-Day Range$4.39▼$6.3652-Week Range$4.23▼$11.26Volume2,213 shsAverage Volume143,008 shsMarket Capitalization$154.86 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get TELA Bio alerts: Email Address TELA Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside107.0% Upside$13.00 Price TargetShort InterestBearish4.58% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.49) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.22 out of 5 starsMedical Sector515th out of 918 stocksSurgical & Medical Instruments Industry62nd out of 100 stocks 3.5 Analyst's Opinion Consensus RatingTELA Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTELA Bio has only been the subject of 2 research reports in the past 90 days.Read more about TELA Bio's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.58% of the outstanding shares of TELA Bio have been sold short.Short Interest Ratio / Days to CoverTELA Bio has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in TELA Bio has recently increased by 22.03%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTELA Bio does not currently pay a dividend.Dividend GrowthTELA Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TELA. Previous Next 2.9 News and Social Media Coverage News SentimentTELA Bio has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for TELA Bio this week, compared to 1 article on an average week.Search Interest4 people have searched for TELA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TELA Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.00% of the stock of TELA Bio is held by insiders.Percentage Held by Institutions94.35% of the stock of TELA Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TELA Bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TELA Bio are expected to grow in the coming year, from ($1.49) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TELA Bio is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TELA Bio is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTELA Bio has a P/B Ratio of 8.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TELA Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About TELA Bio Stock (NASDAQ:TELA)TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.Read More TELA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TELA Stock News HeadlinesMay 20 at 4:03 PM | globenewswire.comTELA Bio Appoints Greg Firestone as Chief Commercial OfficerMay 13, 2024 | finance.yahoo.comTELA Bio, Inc. (NASDAQ:TELA) Q1 2024 Earnings Call TranscriptMay 12, 2024 | investing.comTELA Bio stock target cut, keeps overweight rating on first quarter resultsMay 12, 2024 | msn.comTELA Bio Reports Strong First Quarter Growth, Expands Product PortfolioMay 12, 2024 | msn.comTELA Bio Awards Stock Units to New Employees as Hiring InducementMay 12, 2024 | americanbankingnews.comTELA Bio (NASDAQ:TELA) Rating Reiterated by Piper SandlerMay 11, 2024 | finance.yahoo.comTELA Bio First Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.63 loss in 1Q 2023)May 11, 2024 | finance.yahoo.comTELA Bio Inc (TELA) Reports Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Continued GrowthMay 11, 2024 | markets.businessinsider.comTELA Bio’s Robust Growth and Promising Outlook Merit Bullish StanceMay 10, 2024 | globenewswire.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2024 | globenewswire.comTELA Bio Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on TELA Bio (TELA)May 3, 2024 | msn.comScoPo’s Powerplays: ASX Health stocks rise in big week of quarterly reportsApril 25, 2024 | globenewswire.comTELA Bio to Announce First Quarter 2024 Financial ResultsApril 17, 2024 | msn.comTELA Bio Launches Innovative Hernia Repair Device in the U.S. MarketApril 16, 2024 | msn.comTELA Bio launches OviTex IHR for inguinal hernia repair in USApril 15, 2024 | globenewswire.comTELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia ProceduresApril 11, 2024 | finance.yahoo.comMDXG: Legal AvenuesApril 10, 2024 | msn.comTELA Bio Appoints Esteemed Surgeon Dr. Howard N. Langstein as Vice President of Medical AffairsApril 8, 2024 | finanznachrichten.deTELA Bio, Inc.: TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon StrategyApril 8, 2024 | globenewswire.comTELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon StrategyMarch 25, 2024 | msn.comTELA Bio Stands Tall With Consistent Growth, Novel Products, and a Promising Revenue Projection for 2024March 24, 2024 | finance.yahoo.comAnalysts Are Updating Their TELA Bio, Inc. (NASDAQ:TELA) Estimates After Its Full-Year ResultsMarch 23, 2024 | seekingalpha.comTELA Bio, Inc. (TELA) Q4 2023 Earnings Call TranscriptMarch 23, 2024 | finance.yahoo.comTELA Bio Full Year 2023 Earnings: US$2.04 loss per share (vs US$2.72 loss in FY 2022)See More Headlines Receive TELA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TELA Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/21/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:TELA CUSIPN/A CIK1561921 Webwww.telabio.com Phone484-320-2930FaxN/AEmployees227Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$15.00 Low Stock Price Target$10.00 Potential Upside/Downside+107.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,660,000.00 Net Margins-63.82% Pretax Margin-63.82% Return on Equity-155.26% Return on Assets-48.61% Debt Debt-to-Equity Ratio2.83 Current Ratio4.13 Quick Ratio3.23 Sales & Book Value Annual Sales$58.45 million Price / Sales2.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book8.14Miscellaneous Outstanding Shares24,660,000Free Float23,176,000Market Cap$154.62 million OptionableOptionable Beta1.00 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Antony Koblish (Age 58)Co-founder, President, CEO & Director Comp: $967.67kMr. Roberto E. Cuca J.D. (Age 56)CFO & COO Comp: $643.37kMr. Paul Talmo (Age 52)Chief Technology Officer Comp: $561.6kMs. Megan Smeykal (Age 48)VP, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer Mr. D. Taylor OcasioGeneral Counsel & Corporate SecretaryMs. Jennifer Lou Armstrong (Age 54)Senior Vice President of Human Resources Mr. Gregory A. Firestone (Age 65)Chief Business Officer Mr. Michael LeonardSenior Vice President of Technical OperationsMr. Peter C. Murphy (Age 51)Chief Commercial Officer Comp: $542.34kLouisa SmithInvestor Relations Contact OfficerMore ExecutivesKey CompetitorsAccurayNASDAQ:ARAYClearPoint NeuroNASDAQ:CLPTCVRxNASDAQ:CVRXQuipt Home MedicalNASDAQ:QIPTKORU Medical SystemsNASDAQ:KRMDView All CompetitorsInsiders & InstitutionsFirst Light Asset Management LLCBought 199,387 shares on 5/15/2024Ownership: 11.168%Vanguard Group Inc.Bought 7,199 shares on 5/10/2024Ownership: 4.081%Russell Investments Group Ltd.Bought 49,204 shares on 5/8/2024Ownership: 0.385%HighMark Wealth Management LLCBought 193,811 shares on 4/29/2024Ownership: 0.786%Gregory A FirestoneBought 2,600 shares on 12/5/2023Total: $14,690.00 ($5.65/share)View All Insider TransactionsView All Institutional Transactions TELA Stock Analysis - Frequently Asked Questions Should I buy or sell TELA Bio stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TELA Bio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TELA shares. View TELA analyst ratings or view top-rated stocks. What is TELA Bio's stock price target for 2024? 3 brokers have issued 12 month price targets for TELA Bio's shares. Their TELA share price targets range from $10.00 to $15.00. On average, they predict the company's stock price to reach $13.00 in the next year. This suggests a possible upside of 107.0% from the stock's current price. View analysts price targets for TELA or view top-rated stocks among Wall Street analysts. How have TELA shares performed in 2024? TELA Bio's stock was trading at $6.62 on January 1st, 2024. Since then, TELA shares have decreased by 5.1% and is now trading at $6.28. View the best growth stocks for 2024 here. When is TELA Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our TELA earnings forecast. How were TELA Bio's earnings last quarter? TELA Bio, Inc. (NASDAQ:TELA) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.25. The company earned $16.60 million during the quarter, compared to the consensus estimate of $15.90 million. TELA Bio had a negative trailing twelve-month return on equity of 155.26% and a negative net margin of 63.82%. During the same quarter last year, the business earned ($0.63) EPS. What ETF holds TELA Bio's stock? Jacob Forward ETF holds 22,967 shares of TELA stock, representing 3.91% of its portfolio. What guidance has TELA Bio issued on next quarter's earnings? TELA Bio updated its FY 2024 earnings guidance on Friday, May, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $74.5 million-$76.5 million, compared to the consensus revenue estimate of $74.9 million. What other stocks do shareholders of TELA Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other TELA Bio investors own include Micron Technology (MU), Intel (INTC), Pfizer (PFE), CrowdStrike (CRWD), Walt Disney (DIS), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Alteryx (AYX) and Cisco Systems (CSCO). When did TELA Bio IPO? TELA Bio (TELA) raised $60 million in an IPO on Friday, November 8th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. Who are TELA Bio's major shareholders? TELA Bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include First Light Asset Management LLC (11.17%), Vanguard Group Inc. (4.08%), HighMark Wealth Management LLC (0.79%) and Russell Investments Group Ltd. (0.39%). Insiders that own company stock include Antony Koblish, Ew Healthcare Partners Fund 2,, Gregory A Firestone, Opaleye Management Inc, Orbimed Advisors Llc and Roberto Cuca. View institutional ownership trends. How do I buy shares of TELA Bio? Shares of TELA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TELA) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBill Gates is all about this tiny $2 stockTimothy SykesThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TELA Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.